Losartan Reduces Trinitrobenzene Sulphonic Acid-Induced Colorectal Fibrosis in Rats | Zendy

Dov Wengrower | Zendy; G. Zanninelli | Zendy; Giovanni Latella | Zendy; Stefano Necozione | Zendy; Issa Metanes | Zendy; Eran Israeli | Zendy; Joseph Lysy | Zendy; Mark Pines | Zendy; Orit Papo | Zendy; Eran Goldin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Losartan Reduces Trinitrobenzene Sulphonic Acid-Induced Colorectal Fibrosis in Rats

Author(s) -

Dov Wengrower,

G. Zanninelli,

Giovanni Latella,

Stefano Necozione,

Issa Metanes,

Eran Israeli,

Joseph Lysy,

Mark Pines,

Orit Papo,

Eran Goldin

Publication year - 2012

Publication title -

canadian journal of gastroenterology

Language(s) - English

Resource type - Journals

eISSN - 1916-7237

pISSN - 0835-7900

DOI - 10.1155/2012/628268

Subject(s) - losartan , fibrosis , medicine , angiotensin ii , crohn's disease , cytokine , extracellular matrix , inflammatory bowel disease , disease , immunology , receptor , biology , microbiology and biotechnology

Intestinal fibrosis is a challenging clinical condition in several fibrostenosing enteropathies, particularly Crohn's disease. Currently, no effective preventive measures or medical therapies are available for intestinal fibrosis. Fibrosis, due to an abnormal accumulation of extracellular matrix proteins, is a chronic and progressive process mediated by cell⁄matrix⁄cytokine and growth factor interactions, but may be a reversible phenomenon. Of the several molecules regulating fibrogenesis, transforming growth factor-beta 1 (TGF-b1) appears to play a pivotal role; it is strongly induced by the local activation of angiotensin II. The levels of both TGF-b1 and angiotensin II are elevated in fibrostenosing Crohn's disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research